| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/26/2006 | WO2006009325A1 Metalloprotease inhibitor |
| 01/26/2006 | WO2006009309A1 Galectin 9-binding protein factor |
| 01/26/2006 | WO2006009092A1 Method of effectively using medicine and method concerning prevention of side effect |
| 01/26/2006 | WO2006008881A1 Peroral vaccine carrier system |
| 01/26/2006 | WO2006008779A1 Use of hmgb1 for wound healing |
| 01/26/2006 | WO2006008582A1 Treatment of neurological disorders with hematopoeitic growth factors |
| 01/26/2006 | WO2006008556A1 Imidazole and thiazole derivatives as antiviral agents |
| 01/26/2006 | WO2006008270A1 Use of compounds containing thiol groups as an efflux pump inhibitor |
| 01/26/2006 | WO2006008142A1 Diagnosis and therapy of psoriasis vulgaris |
| 01/26/2006 | WO2006007881A2 New pharmaceutical compositions based on fluorenecarboxyclic acid esters and soluble tnf receptor fusion proteins |
| 01/26/2006 | WO2006007857A1 Bilf1, a constitutive active g-protein coupled receptor |
| 01/26/2006 | WO2006007854A1 Gus3 neuropeptides for regulating hypothalamic function |
| 01/26/2006 | WO2006007780A1 Injectable bone-repairing bioactive material capable of forming gel and its preparation method |
| 01/26/2006 | WO2006007682A1 Polypeptides for use in ameliorating effects of aging in mammals |
| 01/26/2006 | WO2005120539A3 Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| 01/26/2006 | WO2005112657B1 Method of making protein hydrolysates enriched in aminoacids and the use thereof for the production of functional food and medical food |
| 01/26/2006 | WO2005110445A3 Methods and compositions for the dietary management of autoimmune disorders |
| 01/26/2006 | WO2005108562A3 Synthetic fluorouridine-activating enzyme for cancer therapy |
| 01/26/2006 | WO2005097161A3 Gpe and g-2mepe, caffeine and alkanol for treatment of cns injury |
| 01/26/2006 | WO2005094871A3 Bmp-3 propeptides and related methods |
| 01/26/2006 | WO2005082398A3 Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells |
| 01/26/2006 | WO2005070394A3 Ternary non-lamellar lipid compositions |
| 01/26/2006 | WO2005048927A3 Methods and reagents for the treatment of inflammatory disorders |
| 01/26/2006 | WO2005005462A3 Blys antagonists and uses thereof |
| 01/26/2006 | WO2004094621A3 Polynucleotide encoding a novel trp channel family member, ltrpc3, and splice variants thereof |
| 01/26/2006 | WO2004060307A3 Synthetic neutropoiesis-stimulating proteins |
| 01/26/2006 | WO2004053098A3 Base, a new cancer gene, and uses thereof |
| 01/26/2006 | WO2004045532A3 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 01/26/2006 | WO2004013160A3 Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
| 01/26/2006 | US20060021088 Identification of novel e2f target genes and use thereof |
| 01/26/2006 | US20060020117 Partial extraction of the antithrombin during the fractionation of human plasma so that the final albumin has an active antithrombin content equal to or greater than 0.03 mg/g of albumin |
| 01/26/2006 | US20060020116 Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| 01/26/2006 | US20060020114 Apo-2DcR |
| 01/26/2006 | US20060020113 Human Six Transmembrane Epithelial Antigen of the Prostate (STEAP) protein; folds in a "serpentine" manner into three extracellular and two intracellular loops; used for diagnosis and treatment of prostate cancer |
| 01/26/2006 | US20060020110 Synthetic peptides that bind to the hepatitis B virus core and E antigens |
| 01/26/2006 | US20060020109 Synthetic peptides to treat an autoimmune demylinating disease e.g., multiple sclerosis; an amino acid sequence having two tyrosine residues and a lysine complex with the myelin basic protein to modulate an immune response |
| 01/26/2006 | US20060019945 Granzyme b inhibitors |
| 01/26/2006 | US20060019915 Method to modulate the immune system with a novel guanine nucleotide exchange factor |
| 01/26/2006 | US20060019914 Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes |
| 01/26/2006 | US20060019905 Hepatitis C inhibitor peptide analogs |
| 01/26/2006 | US20060019904 Composition for promoting lacrimal secretion |
| 01/26/2006 | US20060019903 Compositions and methods for treating precocious puberty |
| 01/26/2006 | US20060019902 PTH-like peptides |
| 01/26/2006 | US20060019901 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 01/26/2006 | US20060019900 Alpha-4 beta-1 integrin ligands for imaging and therapy |
| 01/26/2006 | US20060019899 EphA2 T-cell epitopes and uses therefor |
| 01/26/2006 | US20060019898 Methods of treating intestinal ischemia using heparin-binding epidermal growth factor |
| 01/26/2006 | US20060019897 Anti-angiogenic polypeptides |
| 01/26/2006 | US20060019896 Netrin-related compositions and uses |
| 01/26/2006 | US20060019895 Using soluble frizzled related protein 3 (SFRP-3) and/or Dickkopf-1 (DKK1) expression profiles as evaluative tools in prediciting/diagnosing bone disorders in cancer patients |
| 01/26/2006 | US20060019894 Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage |
| 01/26/2006 | US20060019892 Conopeptides and methods of use |
| 01/26/2006 | US20060019891 combinations of platelet derived growth factor, vascular endothelial growth factor, and angiopoietin-2 |
| 01/26/2006 | US20060019890 Method for treating cardiac remodeling following myocardial injury |
| 01/26/2006 | US20060019889 Anti-osteolytic therapy involving adiponectin |
| 01/26/2006 | US20060019888 such as viral myocarditis (Coxsackie virus, echovirus, polio virus) or dilated (congestive) cardiomyopathy, by binding ErbB2-ErbB4 receptors; atpase inhibitors |
| 01/26/2006 | US20060019887 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| 01/26/2006 | US20060019886 Monomer protein with bone morphogenetic activity and medicinal agent containing the same for preventing and treating diseases of cartilage and bone |
| 01/26/2006 | US20060019885 Modified bryodin 1 with reduced immunogenicity |
| 01/26/2006 | US20060019884 Peptide composition |
| 01/26/2006 | US20060019883 Use of cyclin D1 inhibitors |
| 01/26/2006 | US20060019882 Use of Yops as caspase inhibitor |
| 01/26/2006 | US20060019881 Human spasmolytic polypeptide in glycosylated form |
| 01/26/2006 | US20060019880 Modulation of synaptogenesis |
| 01/26/2006 | US20060019879 Polynucleotide encoding autoantigens associated with endometriosis |
| 01/26/2006 | US20060019878 Polynucleotide encoding autoantigens associated with endometriosis |
| 01/26/2006 | US20060019877 Hasylated polypeptides |
| 01/26/2006 | US20060019876 Targeted delivery of bioaffecting compounds for the treatment of cancer |
| 01/26/2006 | US20060019875 Hydrocephalus shunt having a ventricular catheter with adiponectin as a coating on an outer surface |
| 01/26/2006 | US20060019874 Cation complexes of insulin compund conjugates, formulation and uses thereof |
| 01/26/2006 | US20060019873 treating insulin deficiencies or otherwise supplementing insulin in a subject using the insulin compound conjugates, cation-insulin compound conjugate complexes, and/or formulations of the invention; diabetes; improved oral bioavailability |
| 01/26/2006 | US20060019872 Oral formulations for poorly absorptive hydrophilic drugs |
| 01/26/2006 | US20060019871 Endothelial cell apoptosis induced by fibrinogen gamma chain C-terminal fragment |
| 01/26/2006 | US20060019870 Apoprotein cochleate compositions |
| 01/26/2006 | US20060019869 Intradiscal anti-inflammatory therapy involving autologous adiponectin |
| 01/26/2006 | US20060019868 Biocompatible liquid, biocompatible gas, and solid particles of a biocompatible polymer are mixed together to form a homogenous composition including a discontinuous gas phase with solid particles homogenously dispersed throughout a continuous liquid phase |
| 01/26/2006 | US20060019392 Novel bone mineralization proteins, DNA, vectors, expression systems |
| 01/26/2006 | US20060019386 Protein domain related to deafness, osteoarthritis and abnormal cell proliferation |
| 01/26/2006 | US20060019365 IKK-alpha proteins, nucleic acids and methods |
| 01/26/2006 | US20060019346 Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands |
| 01/26/2006 | US20060019344 C-erbB-2 external domain: gp75 |
| 01/26/2006 | US20060019336 Factor VII or VIIa - like molecules |
| 01/26/2006 | US20060019322 Nucleotide sequence coding polypeptide for use in diagnosis and therapy of prostate cancer |
| 01/26/2006 | US20060019320 Wnt mediated erbb signalling, compositions and uses related thereto |
| 01/26/2006 | US20060019310 Cell regulatory genes, encoded products, and uses related thereto |
| 01/26/2006 | US20060019281 Gene for which is located on the short arm of human chromosome 1; gene is directly implicated in colon, kidney and breast cancers |
| 01/26/2006 | US20060019261 RNA-binding protein |
| 01/26/2006 | US20060019248 mutant SH3-binding protein (SH3BP2) nucleic acids, polypeptides, and agents which selectively bind to the mutant SH3BP2 molecules and which do not bind to the wild type SH3BP2 molecules |
| 01/26/2006 | US20060019241 Na+ and CI-coupled transport system for endogenous opioid peptides |
| 01/26/2006 | US20060019240 Posh nucleic acids, polypeptides and related methods |
| 01/26/2006 | US20060018973 Composition for stimulating bone-formation and bone consolidation |
| 01/26/2006 | US20060018971 Nucleic acid microspheres, production and delivery thereof |
| 01/26/2006 | US20060018958 Soft gel formulation includes Coenzyme Q10, Vitamin E, beta-carotene, bee's wax, medium chain triglycerides available as MCT Myglyol S12, and rice bran oil formulated to maximize the body's absorption |
| 01/26/2006 | US20060018946 such as temporomandibular joint disorders, osteoarthritis of the knee, hip and other types of inflammatory joint diseases; identifying specific matrix metalloproteinase; and injecting a polymer gel with the component the MMP(s) seek to destroy, thus preserving the joint and allowing time to heal |
| 01/26/2006 | US20060018925 Compositions and methods for modulating RSV infection and immunity |
| 01/26/2006 | US20060018921 Histone deacetylase inhibitors and cognitive applications |
| 01/26/2006 | US20060018917 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers |
| 01/26/2006 | US20060018915 Heteroclitic analogs and related methods |
| 01/26/2006 | US20060018914 Novel antibody conjugates reactive with human carcinomas |
| 01/26/2006 | US20060018906 monoclonal antibody for treating cancer, neovascularization, vascular and arthritic diseases; immunoassay; immunotherapy; inhibition or antagonism of TNF decreases expression of Vascular Endothelial Growth Factor (VEGF) or Vascular Permeability Factor (VPF); decrease angiogenesis |